A股異動 | 華仁藥業(300110.SZ)放量大漲13% 前三季淨利增超110% 並擬收購
格隆匯10月27日丨華仁藥業(300110.SZ)早盤一度逼近漲停,現報6.17元,漲12.8%,成交額放大至7.58億元,總市值73億元。華仁藥業26日公佈,公司前三季度實現營業收入10.13億元,同比下降7.19%;歸屬於上市公司股東的淨利潤5409.83萬元,同比增長112.11%。另外,公司擬收購廣西裕源及浦北新科各100%股權。此次收購後,能夠快速補齊公司的大輸液品種和品規,與公司現有品種和產線相互結合,形成公司輸液產品高中低檔全覆蓋的產品結構,降低生產成本,拓展銷售渠道。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.